Form 8-K - Current report:
SEC Accession No. 0001837607-24-000013
Filing Date
2024-03-29
Accepted
2024-03-29 15:46:29
Documents
17
Period of Report
2024-03-29
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K aeon-20240329x8k.htm   iXBRL 8-K 44211
2 EX-99.1 aeon-20240329xex99d1.htm EX-99.1 270863
3 GRAPHIC aeon-20240329xex99d1001.jpg GRAPHIC 3801
  Complete submission text file 0001837607-24-000013.txt   527889

Data Files

Seq Description Document Type Size
4 EX-101.SCH aeon-20240329.xsd EX-101.SCH 4363
5 EX-101.DEF aeon-20240329_def.xml EX-101.DEF 14404
6 EX-101.LAB aeon-20240329_lab.xml EX-101.LAB 16787
7 EX-101.PRE aeon-20240329_pre.xml EX-101.PRE 14792
20 EXTRACTED XBRL INSTANCE DOCUMENT aeon-20240329x8k_htm.xml XML 7177
Mailing Address 5 PARK PLAZA SUITE 1750 IRVINE CA 92614
Business Address 5 PARK PLAZA SUITE 1750 IRVINE CA 92614 (949) 354-6499
AEON Biopharma, Inc. (Filer) CIK: 0001837607 (see all company filings)

EIN.: 853940478 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40021 | Film No.: 24804000
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)